Login to Your Account



Roche plans to revisit gantenerumab in phase III AD program

By Michael Fitzhugh
Staff Writer

Tuesday, March 7, 2017

Roche Holding AG plans to initiate a pair of new pivotal phase III studies testing the beta-amyloid-targeting monoclonal antibody gantenerumab in patients with prodromal to mild AD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription